16.76
-0.69 (-3.95%)
| Previous Close | 17.45 |
| Open | 17.17 |
| Volume | 2,613,898 |
| Avg. Volume (3M) | 2,846,139 |
| Market Cap | 1,756,233,216 |
| Price / Earnings (Forward) | 3.75 |
| Price / Sales | 0.740 |
| Price / Book | 1.49 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sarepta Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.40 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Wells Fargo, 126.73%) | Buy |
| Median | 34.00 (102.86%) | |
| Low | 5.00 (HC Wainwright & Co., -70.17%) | Sell |
| Average | 25.67 (53.16%) | |
| Total | 2 Buy, 1 Sell | |
| Avg. Price @ Call | 18.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Mar 2026 | 5.00 (-70.17%) | Sell | 16.32 |
| 27 Jan 2026 | 5.00 (-70.17%) | Sell | 22.17 | |
| Wells Fargo | 27 Feb 2026 | 38.00 (126.73%) | Buy | 16.76 |
| Wedbush | 23 Jan 2026 | 34.00 (102.86%) | Buy | 21.13 |
| 09 Dec 2025 | 32.00 (90.93%) | Buy | 22.17 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ESTEPAN IAN MICHAEL | - | 16.32 | -4,176 | -68,152 |
| RODINO-KLAPAC LOUISE | - | 16.32 | -4,485 | -73,195 |
| ROTHFUSS CRISTIN | - | 16.32 | -408 | -6,659 |
| WONG RYAN HO-YAN | - | 16.32 | -450 | -7,344 |
| Aggregate Net Quantity | -9,519 | |||
| Aggregate Net Value ($) | -155,350 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.32 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RODINO-KLAPAC LOUISE | Officer | 02 Mar 2026 | Disposed (-) | 4,485 | 16.32 | 73,195 |
| ESTEPAN IAN MICHAEL | Officer | 02 Mar 2026 | Disposed (-) | 4,176 | 16.32 | 68,152 |
| WONG RYAN HO-YAN | Officer | 02 Mar 2026 | Disposed (-) | 450 | 16.32 | 7,344 |
| ROTHFUSS CRISTIN | Officer | 02 Mar 2026 | Disposed (-) | 408 | 16.32 | 6,659 |
| RODINO-KLAPAC LOUISE | Officer | 01 Mar 2026 | Option execute | 8,125 | - | - |
| ESTEPAN IAN MICHAEL | Officer | 01 Mar 2026 | Option execute | 8,125 | - | - |
| ESTEPAN IAN MICHAEL | Officer | 26 Feb 2026 | Option execute | 7,450 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |